细胞凋亡在胰腺癌治疗中的作用

doi:10.11904/j.issn.1002-3070.2016.04.016

摘要/Abstract

摘要： 胰腺癌(Pancreatic adenocarcinoma,PAC)由于发病因素多、病情隐匿不易诊断、对放化疗不敏感而导致预后极差。细胞凋亡信号通路阻断可能是导致胰腺癌对传统放化疗不敏感的关键原因。本综述拟梳理胰腺癌细胞内部凋亡失衡主要信号通路,总结细胞凋亡诱导关键信号通路等在胰腺癌治疗中的基础研究进展,以期为拓展胰腺癌细胞凋亡的理解和开发凋亡相关靶向分子治疗提供新思路。

关键词: 细胞凋亡, 胰腺癌, 信号通路, 靶向治疗

Abstract: Pancreatic adenocarcinoma(PAC)is still a refractory human digest malignancies due to multifaceted causes,late diagnosis and insensitive to traditional chemo-and radio-therapy.Resistance to apoptosis could be one of the most relevant mechanisms for PAC to escape any non-surgical therapy.This review aims to clear up the main deregulated apoptosis signal pathways over the years and to find out the abnormal molecule target(s),and therefore,provide novel concepts for PAC molecular targeting therapy.

Key words: Apoptosis, Pancreatic cancer, Signal pathway, Target therapy

中图分类号:

R375.9

赵相轩,温锋综述,卢再鸣审校. 细胞凋亡在胰腺癌治疗中的作用[J]. 实用肿瘤学杂志, 2016, 30(4): 375-379.

ZHAO Xiangxuan,WEN Feng,LU Zaiming. The role of apoptosis in pancreatic cancer therapy[J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(4): 375-379.

参考文献

1 Lin QJ,Yang F,Jin C,et al.Current status and progress of pancreatic cancer in China[J].World J Gastroenterol,2015,21(26):7988-8003.
2 Arlt A,Muerkoster SS,Schafer H.Targeting apoptosis pathways in pancreatic cancer[J].Cancer Lett,2013,332(2):346-358.
3 Dao P,Smith N,Scott-Algara D,et al.Restoration of TRAIL-induced apoptosis in resistant human pancreatic cancer cells by a novel FAK inhibitor,PH11[J].Cancer Lett,2015,360(1):48-59.
4 Yu R,Albarenque SM,Cool RH,et al.DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer[J].Cancer Biol Ther,2014,15(12):1658-1666.
5 Cristofanon S,Fulda S.ABT-737 promotes tBid mitochondrial accumulation to enhance TRAIL-induced apoptosis in glioblastoma cells[J].Cell Death Dis,2012,3:e432.
6 Wang G,Zhan Y,Wang H,et al.ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein[J].Cancer Chemother Pharmacol,2012,69(3):799-805.
7 Murtaza I,Saleem M,Adhami VM,et al.Suppression of cFLIP by lupeol,a dietary triterpene,is sufficient to overcome resistance to TRAIL-mediated apoptosis in chemoresistant human pancreatic cancer cells[J].Cancer Res,2009,69(3):1156-1165.
8 Kim H,Buchsbaum DJ,Zinn KR.A novel imaging biomarker extracted from fluorescence microscopic imaging of TRA-8/DR5 oligomers predicts TRA-8 therapeutic efficacy in breast and pancreatic cancer mouse models[J].Mol Imaging Biol,2016,18(3):325-333.
9 Prabhu L,Mundade R,Korc M,et al.Critical role of NF-kappaB in pancreatic cancer[J].Oncotarget,2014,5(22):10969-10975.
10 Li F,Zhang J,Arfuso F,et al.NF-kappaB in cancer therapy[J].Arch Toxicol,2015,89(5):711-731.
11 Arlt A,Muerkoster SS,Schafer H.Targeting apoptosis pathways in pancreatic cancer[J].Cancer Lett,2013,332(2):346-358.
12 Lo M,Ling V,Low C,et al.Potential use of the anti-inflammatory drug,sulfasalazine,for targeted therapy of pancreatic cancer[J].Curr Oncol,2010,17(3):9-16.
13 Sirohi B,Singh A,Dawood S,et al.Advances in chemotherapy for pancreatic cancer[J].Indian J Surg Oncol,2015,6(1):47-56.
14 Nedaeinia R,Avan A,Manian M,et al.EGFR as a potential target for the treatment of pancreatic cancer:dilemma and controversies[J].Curr Drug Targets,2014,15(14):1293-1301.
15 Arnoletti JP,Frolov A,Eloubeidi M,et al.A phase I study evaluating the role of the anti-epidermal growth factor receptor(EGFR)antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer[J].Cancer Chemother Pharmacol,2011,67(4):891-897.
16 Strumberg D,Schultheis B,Scheulen ME,et al.Phase II study of nimotuzumab,a humanized monoclonal anti-epidermal growth factor receptor(EGFR)antibody,in patients with locally advanced or metastatic pancreatic cancer[J].Invest New Drugs,2012,30(3):1138-1143.
17 Boeck S,Jung A,Laubender RP,et al.EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer:translational results from the randomised,crossover phase 3 trial AIO-PK0104[J].Br J Cancer,2013,108(2):469-476.
18 Pan Y,Zheng M,Zhong L,et al.A preclinical evaluation of SKLB261,a multikinase inhibitor of EGFR/Src/VEGFR2,as a therapeutic agent against pancreatic cancer[J].Mol Cancer Ther,2015,14(2):407-418.
19 Huguet F,Fernet M,Giocanti N,et al.Afatinib,an irreversible EGFR family inhibitor,shows activity toward pancreatic cancer cells,alone and in combination with radiotherapy,independent of KRAS status[J].Target Oncol,2015,5(1):1-11.
20 Boeck S,Jung A,Laubender RP,et al.KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer[J].J Gastroenterol,2013,48(4):544-548.
21 Zheng H,Liu A,Liu B,et al.Ras homologue enriched in brain is a critical target of farnesyltransferase inhibitors in non-small cell lung cancer cells[J].Cancer Lett,2010,297(1):117-125.
22 Roy SK,Srivastava RK,Shankar S.Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor,leading to cell cycle arrest and apoptosis in pancreatic cancer[J].J Mol Signal,2010,5(1):10-21.
23 Hao F,Kang J,Cao Y,et al.Curcumin attenuates palmitate-induced apoptosis in MIN6 pancreatic beta-cells through PI3K/Akt/FoxO1 and mitochondrial survival pathways[J].Apoptosis,2015,20(11):1420-1432.
24 Li W,Ma J,Ma Q,et al.Resveratrol inhibits the epithelial-mesenchymal transition of pancreatic cancer cells via suppression of the PI-3K/Akt/NF-kappaB pathway[J].Curr Med Chem,2013,20(33):4185-4194.
25 Sharma N,Nanta R,Sharma J,et al.PI3K/AKT/mTOR and sonic hedgehog pathways cooperate together to inhibit human pancreatic cancer stem cell characteristics and tumor growth[J].Oncotarget,2015,6(31):32039-32060.
26 Kristensen A,Vagnildhaug OM,Gronberg BH,et al.Does chemotherapy improve health-related quality of life in advanced pancreatic cancer? A systematic review[J].Crit Rev Oncol Hematol,2016,99(6):286-298.
27 Damaskos C,Karatzas T,Nikolidakis L,et al.Histone deacetylase(HDAC)inhibitors:current evidence for therapeutic activities in pancreatic cancer[J].Anticancer Res,2015,35(6):3129-3135.
28 Bauden M,Tassidis H,Ansari D.In vitro cytotoxicity evaluation of HDAC inhibitor apicidin in pancreatic carcinoma cells subsequent time and dose dependent treatment[J].Toxicol Lett,2015,236(1):8-15.
29 Minjie S,Defei H,Zhimin H,et al.Targeting pancreatic cancer cells by a novel hydroxamate-based histone deacetylase(HDAC)inhibitor ST-3595[J].Tumour Biol,2015,36(11):9015-9022.
30 Park SJ,Kim SM,Moon JH,et al.SAHA,an HDAC inhibitor,overcomes erlotinib resistance in human pancreatic cancer cells by modulating E-cadherin[J].Tumour Biol,2015,54(3):1-8.
31 Hong L,Han Y,Li S,et al.The malignant phenotype-associated microRNA in gastroenteric,hepatobiliary and pancreatic carcinomas[J].Expert Opin Biol Ther,2010,10(12):1693-1701.
32 Srivastava SK,Bhardwaj A,Arora S,et al.MicroRNA-345 induces apoptosis in pancreatic cancer cells through potentiation of caspase-dependent and-independent pathways[J].Br J Cancer,2015,113(4):660-668.
33 Liu Z,Xu Y,Long J,et al.microRNA-218 suppresses the proliferation,invasion and promotes apoptosis of pancreatic cancer cells by targeting HMGB1[J].Chin J Cancer Res,2015,27(3):247-257.
34 Guo R,Wang Y,Shi WY,et al.MicroRNA miR-491-5p targeting both TP53 and Bcl-XL induces cell apoptosis in SW1990 pancreatic cancer cells through mitochondria mediated pathway[J].Molecules,2012,17(12):14733-14747.
35 Wang X,Wang L,Mo Q,et al.A positive feedback loop of p53/miR-19/TP53INP1 modulates pancreatic cancer cell proliferation and apoptosis[J].Oncol Rep,2016,35(1):518-523.
36 Azmi AS,Aboukameel A,Banerjee S,et al.MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function[J].Eur J Cancer,2010,46(6):1122-1131.
37 Camp ER,Wang C,Little EC,et al.Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy[J].Cancer Gene Ther,2013,20(4):222-228.
38 Izetti P,Hautefeuille A,Abujamra AL,et al.PRIMA-1,a mutant p53 reactivator,induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines[J].Invest New Drugs,2014,32(5):783-794.

[1]	朱琳,张春霞. 纳米载药系统靶向肿瘤干细胞的研究进展[J]. 实用肿瘤学杂志, 2019, 33(3): 276-279.
[2]	李珊,赵春波,乔文波. 术中放疗在胰腺癌中的应用进展[J]. 实用肿瘤学杂志, 2019, 33(3): 280-283.
[3]	刘恒辰, 张新宇. Toll样受体信号通路作为结直肠癌潜在治疗靶点的研究进展[J]. 实用肿瘤学杂志, 2019, 33(2): 188-192.
[4]	罗干, 易超, 依马木买买提江·阿布拉, 徐林, 尹继炜, 丁伟. Notch信号通路在胰腺癌中的表达及其作用研究[J]. 实用肿瘤学杂志, 2019, 33(1): 1-7.
[5]	丁界先, 张津, 陈永刚, 王兴文综述, 王栓科审校. Wnt信号通路与肿瘤发生的研究进展[J]. 实用肿瘤学杂志, 2019, 33(1): 73-77.
[6]	李悦, 徐可, 韩增祥, 孙敏, 樊国华综述, 张勇审校. 结肠癌中肿瘤相关巨噬细胞的作用及靶向治疗的研究进展[J]. 实用肿瘤学杂志, 2018, 32(5): 450-454.
[7]	王元综述, 孙轶华审校. β-连环蛋白在软组织肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(5): 455-459.
[8]	张婷, 贾迪(综述), 杨丹(审校). 骨肉瘤的生物学治疗进展[J]. 实用肿瘤学杂志, 2018, 32(3): 254-257.
[9]	张中民, 庞达. 长链非编码RNA调控癌症细胞信号通路的研究进展[J]. 实用肿瘤学杂志, 2018, 32(2): 184-188.
[10]	黄倩倩, 马建加, 吴强, 刘彬彬, 沐晓芹, 刘树林审校. 肿瘤干细胞及肿瘤靶向治疗的研究进展[J]. 实用肿瘤学杂志, 2017, 31(6): 533-537.
[11]	梁语丝, 谭永刚, 邹华伟审校. 低剂量化疗作用机制的研究进展[J]. 实用肿瘤学杂志, 2017, 31(6): 538-542.
[12]	王吉锡, 邓伟生, 王凤儒, 史之茂, 孟丹, 徐强, 张玉瑶. 甘草提取物的有效部位诱导人宫颈癌HeLa细胞株凋亡及对凋亡相关蛋白Caspase-3和Caspase-9表达的影响[J]. 实用肿瘤学杂志, 2017, 31(5): 390-395.
[13]	黄承路, 韩少辉徐苏琴综述, 赵俊刚审校. 原发性肺黏液腺癌的研究进展[J]. 实用肿瘤学杂志, 2017, 31(5): 463-467.
[14]	孙禹琪,陈秀玮. CTGF/CCN2在恶性肿瘤的发生发展及靶向治疗中的研究进展[J]. 实用肿瘤学杂志, 2017, 31(4): 363-366.
[15]	张绪良, 胡亚华, 黄丹青. 苏林酸在NF-κB对人乳腺癌TNF-α诱导细胞凋亡增敏中的相关作用[J]. 实用肿瘤学杂志, 2017, 31(2): 102-106.